Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebastinib + paclitaxel in solid tumors
NCT03601897Phase 2Terminated
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Oct 2018
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rebastinib in solid tumor, triple-negative breast cancer (TNBC), inflammatory breast cancer (IBC), ovarian cancer, endometrial cancer (EC), sponsored by Deciphera Pharmaceuticals. Started Oct 2018; status: terminated.
02
Drugs
rebastinib
03
Conditions
solid tumortriple-negative breast cancer (TNBC)inflammatory breast cancer (IBC)ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT03601897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03601897.